Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its ...

McGill University researchers have demonstrated that AMPA receptors (AMPARs), which mediate fast excitatory neurotransmission ...

Transfect the cells with the recombinant vector using Lipofectamine ... Use the cells on the coverslip to check the level of GFP fusion protein expression with high-resolution fluorescence ...

Detailed price information for Protalix Biotherapeutics (PLX-A) from The Globe and Mail including charting and trades.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

The Central Board of Secondary Education (CBSE) is conducting the Class 12 board exams for the 2025 academic year. The ...

Protalix BioTherapeutics (NYSE:PLX – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday. Separately, HC Wainwright ...

BEIJING, China I March 24, 2025 I SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for ...

Introduction: the need for advanced monitoring in shake flasks. Shake flasks have been a cornerstone of biotechnological ...

Creative Diagnostics has announced its comprehensive Drug Discovery Services for antiviral therapeutic development. NEW YORK, NY, UNITED ST ...

Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...